Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1593-1602

  Schoffelen, Rafke ^a   Woliner Van Der Weg, Wietske ^a   Visser, Eric P ^a   Goldenberg, David M ^b,c,d   Sharkey, Robert M ^c   McBride, William J ^c   Chang, Chien Hsing ^c   Rossi, Edmund A ^d   Van Der Graaf, Winette T A ^a   Oyen, Wim J G ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GARDEN STATE CANCER CENTER   (United States)

^c IMMUNOMEDICS INC   (United States)

^d IBC Pharmaceuticals Inc   (United States)

Author keywords

Bispecific antibodies; Carcinoembryonic antigen; Dosimetry; Pretargeted radioimmunotherapy (PRIT); Red bone marrow

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CLEMASTINE; DEXAMETHASONE; HAPTEN; IMP 288 I 111; IMP 288 LU 177; INDIUM 111; LUTETIUM 177; PEPTIDE; TRANSCRIPTION FACTOR II; UNCLASSIFIED DRUG; DOTA-TYROSYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)-GLUTAMYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)AMIDE; INDIUM; LUTETIUM; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE MARROW; CLINICAL STUDY; COLORECTAL CANCER; DOSIMETRY; DRUG CLEARANCE; FEMALE; HUMAN; KIDNEY TUBULE ABSORPTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERSONALIZED MEDICINE; PLASMA CLEARANCE; PRETARGETED RADIOIMMUNOTHERAPY; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTOPENIA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; RADIOMETRY; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; INDIVIDUALIZED MEDICINE; LUTETIUM; MALE; MIDDLE AGED; OLIGOPEPTIDES; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOMETRY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84905591345     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2742-6     Document Type: Article

References (41)

1. Baum RP, Rosch F. 1 World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany. World J Nucl Med. 2011;10:1-2.
2. Goldenberg DM, Chang C-H, Rossi EA, McBride WJ, Sharkey RM. Pretargeted molecular imaging and radioimmunotherapy. Theranostics. 2012;2:523-40.
3. Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CML, Franssen GM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109:934-42.
4. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-66. (Pubitemid 19190299)
5. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250-5. (Pubitemid 43093674)
6. Griffiths GL, Chang CH, McBride WJ, et al. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med. 2004;45:30-9. (Pubitemid 47611605)
7. Koppe MJ, Bleichrodt RP, Soede AC, et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004;45:1224-32. (Pubitemid 47611669)
8. McBride WJ, Zanzonico P, Sharkey RM, Norén C, Karacay H, Rossi EA, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678-88. (Pubitemid 47545036)
9. Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, et al. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019-27.
10. Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780-7.
11. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354-63. (Pubitemid 36152493)
12. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158-63.
13. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the Dock and Lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103:6841-6.
14. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282-90.
15. Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, et al. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J Nucl Med. 2012;53:1926-32.
16. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther. 2002;1:553-63.
17. Schoffelen R, van der Graaf WT, Sharkey RM, Franssen GM, McBride WJ, Chang CH, et al. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumour xenografts: a new sensitive detection method. EJNMMI Res. 2012;2:5.
18. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, et al. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 2008;246:497-507.
19. Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005;11:7178s-86s. (Pubitemid 41428721)
20. Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O' Donoghue JA, et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med. 2011;53:82-9.
21. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the Dock-and-Lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190-203.
22. Visser E, Postema E, Boerman O, Visschers J, Oyen W, Corstens F. Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). Eur J Nucl Med Mol Imaging. 2007;34:413-21. (Pubitemid 46295350)
23. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-6. (Pubitemid 30022028)
24. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138-46.
25. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46 Suppl 1:83S-91S. (Pubitemid 47619023)
26. Scala RJ. Biologic effects of ionizing radiation. In: Early PJ, Sodee DB, editors. Principles and practice of nuclear medicine. St Louis: Mosby; 1995. p. 123-7.
27. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46 Suppl 1:99S-106S. (Pubitemid 47619025)
28. Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med. 1999;40:1609-16. (Pubitemid 29471149)
29. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-8.
30. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti- carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38:858-70. (Pubitemid 27251973)
31. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729-39. (Pubitemid 28523499)
32. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435-43.
33. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-23. (Pubitemid 30159851)
34. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results froma phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-94. (Pubitemid 32564871)
35. Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 1998;77:787-95. (Pubitemid 28341398)
36. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591-610. (Pubitemid 28009516)
37. Howell RW, Goddu SM, Rao DV. Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J Nucl Med. 1997;38:727-31. (Pubitemid 127777346)
38. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. 1997;18:592-8. (Pubitemid 28012280)
39. Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, et al. Pharmacokinetics and tumor localization of (111) in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm. 2006;21:106-16. (Pubitemid 43830432)
40. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:814s-9s.
41. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973s-81s. (Pubitemid 37169204)